ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2769

Does Gender Make a Difference in “Composite Psoriatic Disease Activity Index (CPDAI)” in Patients with Psoriatic Arthritis?

Gokce Kenar1, Handan Yarkan2, Berrin Zengin1, Gerçek Can2, Merih Birlik1, Nurullah Akkoc1 and Fatos Onen1, 1Rheumatology, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey, 2Rheumatology, Dokuz Eylul University Faculty of Medicine, İzmir, Turkey

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Disease Activity, measure, psoriasis and psoriatic arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 15, 2016

Title: Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:  “Composite psoriatic disease activity index (CPDAI)” includes 5 domains: peripheral joints, skin, enthesitis, dactylitis, and spinal manifestations in psoriatic arthritis (PsA) which is a heterogeneous disease known with widely variable clinical courses. Experiences in ankylosing spondylitis (AS) studies suggest that female patients report more symptoms and poorer scores on most of the self-reported questionnaires, including Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI) and AS Quality of Life [ASQoL]) despite fewer inflammatory spinal lesions or less radiographic damage as objective disease indicators with respect to male patients. The aims of this study are to investigate the relationship of CPDAI with other follow-up parameters and to evaluate gender differences in these measures in PsA patients.

Methods:  This cross-sectional study included patients with PsA followed up at a Rheumatology outpatient clinic at a university hospital. Disease activity was assessed in the patients by using the CPDAI, BASDAI, Visual Analogue Scale Global (VAS global) and Disease Activity Score (DAS28). Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels were measured in all the patients. The Psoriasis Area and Severity Index (PASI) was used for the measurement of severity of psoriasis. The Patient Acceptable Symptom State (PASS), BASFI, Bath Ankylosing Spondylitis Metrology Index (BASMI), Health Assessment Questionnaire (HAQ), ASQoL and Dermatology Life Quality Index (DLQI) were also evaluated. The correlations were investigated by Spearman’s correlation analysis (rho:<= 0.29 weak, 0.30-0.49 middle, >= 0.50 strong).

Results:  There were 117 patients with PsA (78 female) who fulfilled the Classification Criteria for Psoriatic Arthritis (CASPAR) (3). Their mean CPDAI score was 3.67 (±2.46). The CPDAI was found to be correlated with tender and swollen joint counts, dactylitis and enthesitis. There was a strong correlation between CPDAI and BASDAI, DAS28ESR, DAS28CRP and VAS global. Other follow-up parameters also correlated with CPDAI but no correlation was found between the CPDAI and ESR, CRP and BASMI. Mean CPDAI scores were similar in female and male patients. Female patients with PsA were found as having worse subjective scores including BASDAI, VAS global, BASFI, HAQ, ASQoL scores than males (p<0.05). Whereas objective disease parameters such as mean ESR and serum CRP levels, tender/swollen joint counts, DAS28 and BASMI scores were similar in both gender groups (Table 1).

Conclusion:  This study confirmed that the CPDAI, a new scale to assess disease activity in PsA patients was well correlated with other disease activity measurements. Although subjective disease scores (BASDAI, VAS global, BASFI, HAQ and ASQoL) was higher in female patients, CPDAI was not affected from gender.

Table 1. Demographic and Clinical Data and Disease Activity Measures in Patients with Psoriatic Arthritis
 

Female patients

(n=78)

Male patients

(n=39)

p value

Mean age±SD (yrs) 48.1(±11.7) 45.5 (±12.6) 0.28
Mean education duration±SD (yrs) 8.8 (±4.2) 9.8 (±3.7) 0.26
Mean disease duration±SD (yrs) 7.9 (±8.7) 8.3 (±7.8) 0.80
Dactylitis (%) 6.4 (%) 10.2 (%) 0.48
Entesitis (%) 8.9 (%) 10.2(%) 0.82
CRP (mg/dL±SD) 8.8 (±11.1) 13.2 (±13.9) 0.09
ESR (mm/h±SD) 31.2 (±18.2) 29.3 (±23.2) 0.66
CPDAI (±SD) 3.63 (±2.4) 3.76 (±2.5) 0.79
Tender joint count (±SD) 2.5 (±3.0) 2.1 (±3.0) 0.55
Swollen joint count (±SD) 1.06 (±1.7) 1.1 (±2.1) 0.92
BASDAI (±SD) 4.61 (±2.6) 2.6 (±1.9) 0.00*
BASFI (±SD) 3.4 (±2.8) 1.6 (±1.6) 0.00*
BASMI (±SD) 28.7 (±11.2) 15.0 (±7.0) 0.13
DLQI (±SD) 5.75 (±6.6) 4.45 (±5.9) 0.32
PASI (±SD) 5.26 (±7.6) 8.83 (±11.6) 0.12
HAQ (±SD) 0.85 (±0.7) 0.60 (±0.5) 0.04*
ASQoL (±SD) 8.63 (±5.8) 5.70 (±5.4) 0.01*
VAS global (±SD) 46.12 (±30.5) 30.23 (±26.4) 0.00*
DAS28CRP (±SD) 2.67 (±1.08) 2.53 (±1.08) 0.53
DAS28ESR (±SD) 3.67 (±1.2) 3.25 (±1.4) 0.15
*p<0.05

References: 1. Taylor W. et al. CASPAR Study Group. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum, 2006;54(8):2665-73.


Disclosure: G. Kenar, None; H. Yarkan, None; B. Zengin, None; G. Can, None; M. Birlik, None; N. Akkoc, None; F. Onen, None.

To cite this abstract in AMA style:

Kenar G, Yarkan H, Zengin B, Can G, Birlik M, Akkoc N, Onen F. Does Gender Make a Difference in “Composite Psoriatic Disease Activity Index (CPDAI)” in Patients with Psoriatic Arthritis? [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/does-gender-make-a-difference-in-composite-psoriatic-disease-activity-index-cpdai-in-patients-with-psoriatic-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/does-gender-make-a-difference-in-composite-psoriatic-disease-activity-index-cpdai-in-patients-with-psoriatic-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology